Author:
Woitalla D.,Müller T.,Benz S.,Horowski R.,Przuntek H.
Reference13 articles.
1. Baas H, Harder S, Demisch L, Burklin F, Stecker K, Fischer PA (1995) Fluctuations in Parkinson’s disease. Pathogenetic significance of levodopa’s cerebral pharmacokinetics and pharmacodynamics. J Neural Transm [Suppl] 46: 367–379
2. Behrens S, Sommerville K (2003) Non-oral drug delivery in Parkinson’s disease: a summary from the symposium at the 7th International Congress of Parkinson’s Disease and Movement Disorders, 10-14 November 2002, Miami, FL, USA. Expert Opin Pharmacother 4: 595–599
3. Danhof M, van der Geest R, van Laar T, Bodde HE (1998) An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson’s disease. Adv Drug Delivery Rev 33: 253–263
4. Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 41: 261–309
5. Hoehn MM, Yahr MD (2001) Parkinsonism: onset, progression, and mortality. 1967. Neurology 57: S11–S26
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献